Investigational drug · Phase 3
Utidelone
Not approved by FDA. In 8 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Ovarian Cancer, HER2-negative Breast Cancer Patients With Brain Metastases, Gastric or Gastroesophageal Junction Adenocarcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
8
7 still active
All registered trials
40
Any phase or sponsor naming "Utidelone"
First trial start
2021
Jan 22, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Utidelone", any sponsor or status.
- Phase 229
Conditions studied
As listed on its trial records.
- Ovarian Cancer
- HER2-negative Breast Cancer Patients With Brain Metastases
- Gastric or Gastroesophageal Junction Adenocarcinoma
- Fallopian Tube Cancer
- Primary Peritoneal Cancer
- Non-small Cell Lung Cancer Patients with Brain Metastases
- Gastric Cancer Adenocarcinoma Metastatic
- Bile Duct Cancer
- Advanced Solid Tumor
- Advanced Breast Cancer
Approved drugs for the same conditions: Breast cancer · Non-small cell lung cancer · Small cell lung cancer · Ovarian cancer · Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Utidelone" as an intervention, largest first.
- Utidelone Capsule Combined With Fluoropyrimidine- and Platinum-containing Therapy in First-line Treatment of Patients With Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
Beijing Biostar Pharmaceuticals Co., Ltd.Industry
NCT06841679 · 778 participants (planned) · Start Aug 28, 2025 · Primary completion Sep 1, 2030
Drug: Utidelone Capsule; Utidelone Capsule and 7 more · For: Gastric or Gastroesophageal Junction Adenocarcinoma
Sites: Hialeah, Florida; Anyang, China; Guangzhou, China · 10 sites in all
- Utidelone Versus Docetaxel in Patients With Locally Advanced or Metastatic Non-Small Cell Lung CancerPivotal-lookingStatus unknown
Beijing Biostar Pharmaceuticals Co., Ltd.Industry
NCT05673590 · 612 participants (planned) · Start May 12, 2023 · Primary completion Jun 15, 2025
Drug: Utidelone Injection; Docetaxel Injection · For: Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Sites: Shanghai, China
- Utidelone in Combination With AC Versus Docetaxel in Combination With AC for Neoadjuvant Chemotherapy in Patients With HER2-negative Breast CancerPivotal-lookingStatus unknown
Beijing Biostar Pharmaceuticals Co., Ltd.Industry
NCT05673629 · 552 participants (planned) · Start May 30, 2023 · Primary completion Jun 15, 2025
Drug: Utidelone Injection in combination with AC; Docetaxel Injection in combination with AC · For: Breast Cancer
Sites: Shanghai, China
- Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast CancerPivotal-lookingNot yet recruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05172518 · 512 participants (planned) · Start Mar 1, 2022 · Primary completion Mar 1, 2027
Drug: Taxane plus Intermittent Capecitabine; Utidelone plus Intermittent Capecitabine and 2 more · For: Breast Neoplasms; Locally Advanced or Metastatic Breast Cancer
Sites: Guangzhou, China
- Comparing UTD2 Combined With Capecitabine to Capecitabine as Adjuvant Therapy for Non-pCR TNBC PatientsPivotal-lookingNot yet recruiting
Fudan UniversityAcademic, hospital or other
NCT07021261 · 440 participants (planned) · Start Jun 16, 2025 · Primary completion Jun 16, 2030
Drug: Utidelone plus capecitabine; Capecitabine · For: Breast Cancer; TNBC
- Utidelone Versus Docetaxel in HER2-negative Locally Advanced or Metastatic Breast CancerPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT05430399 · 349 participants (planned) · Start Jun 21, 2022 · Primary completion Jun 1, 2025
Drug: utidelone; docetaxel · For: Breast Neoplasms; Locally Advanced or Metastatic Breast Cancer
Sites: Guangzhou, China; Hunan, China
- Efficacy and Safety of Utidelone Capsule and Utidelone Injection in Patients With HER-2 Negative Advanced Breast CancerPivotal-lookingNot yet recruiting
Beijing Biostar Pharmaceuticals Co., Ltd.Industry
NCT07684456 · 308 participants (planned) · Start Aug 1, 2026 · Primary completion Mar 1, 2028
Drug: Utidelone Capsule; Utidelone Injection and 1 more · For: Advanced Breast Cancer
Sites: Beijing, China
- Organoid-based Functional Precision Therapy for Advanced Breast CancerPivotal-lookingRecruiting
Guangdong Provincial People's HospitalAcademic, hospital or other
NCT06102824 · 252 participants (planned) · Start Oct 1, 2024 · Primary completion Jun 30, 2027
Drug: Organoid-guided treatment; Taxane and 9 more · For: HER2-negative Breast Cancer; Advanced Breast Cancer
Sites: Guangzhou, China
- Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) SubtypePivotal-lookingStatus unknown
Fudan UniversityAcademic, hospital or other
NCT05954442 · 203 participants (planned) · Start Sep 13, 2023 · Primary completion Aug 2025
Drug: Everolimus; Investigator's Choice of Chemotherapy · For: Triple Negative Breast Cancer; Metastatic Breast Cancer; Mutation
Sites: Shanghai, China
- Adaptive Chemotherapy for the Treatment of Advanced Breast CancerPivotal-lookingRecruiting
Sun Yat-sen UniversityAcademic, hospital or other
NCT07088263 · 192 participants (planned) · Start Sep 15, 2025 · Primary completion Jul 24, 2027
Drug: Gemcitabine, Vinorelbine, Eribulin, or Utidelone · For: Breast Neoplasms
Sites: Guangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
- No recurrent severe immune-related hepatitis during PD-L1 therapy after PD-1-related hepatitis in advanced gastroesophageal junction adenocarcinoma: a case report.
Yu K, Jia Y, Chen H, et al. · Semin Oncol 2026
- Utidelone plus PD-1 Inhibitors as Later-Line Combination Treatment in Advanced Solid Tumors after Failure of Multiple Standard Therapies: A Case Series.
Wu L, Chen H, Lin Z, et al. · Case Rep Oncol 2026
- Utidelone-associated chemotherapy-induced peripheral neuropathy: an evidence-stratified narrative review of mechanisms, risk identification, and management strategies.
Li S, Lei L, Luo Y · Front Oncol 2026
- Utidelone in patients with advanced soft tissue sarcoma refractory to anthracycline and antiangiogenic therapy (UTISARC): a single-arm phase II study.
Liu J, Fu Y, Wang B, et al. · BMC Med 2026
- Utidelone exhibits favorable responses in refractory patients with advanced breast cancer.
Bai X, Zhang Q, Xie X, et al. · Transl Cancer Res 2026
- Atrial fibrillation during palliative chemotherapy with utidelone: a case report.
Shen Q, Huang Y, Li H, et al. · Front Oncol 2026
Also in development for Ovarian Cancer
- SHR-A1811Trastuzumab RezetecanPhase 327 trials
Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- GiredestrantRO7197597, GDC-9545Phase 316 trials
Roche (Genentech) · Early Breast Cancer, Breast Cancer, Estrogen Receptor (ER)-Positive, HER2-negative, Locally Advanced or Metastatic Breast Cancer
- SG001enlonstobart, Enlonstobart will be administrated on a 14-day cyclePhase 315 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · HER2-positive Gastric Cancer, Esophageal Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- LBL-024Phase 311 trials
Nanjing Leads Biolabs Co.,Ltd · Advanced Solid Tumour, Advanced Extrapulmonary Neuroendocrine Carcinoma, Metastatic Colorectal Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- SaruparibAZD5305Phase 310 trials
AstraZeneca · Prostate Cancer, Ovarian Cancer, Endometrial Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.